Fabiana Madotto1,2, Emanuele Rezoagli3,4,5, Tài Pham6,7,8, Marcello Schmidt9, Bairbre McNicholas10, Alessandro Protti11,12, Rakshit Panwar13,14, Giacomo Bellani3,15, Eddy Fan4,8,9,16, Frank van Haren17, Laurent Brochard6,7,8, John G Laffey18,19,20. 1. Research Center on Public Health, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. 2. Scientific Institute for Research, Hospitalization and Health Care, IRCCS Multimedica, Sesto San Giovanni, Milan, Italy. 3. Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. 4. Anaesthesia and Intensive Care Medicine, School of Medicine, National University of Ireland Galway, Galway, Ireland. 5. Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, Biomedical Sciences Building, National University of Ireland Galway, Galway, Ireland. 6. Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Canada. 7. Department of Critical Care Medicine, St Michael's Hospital, Toronto, Canada. 8. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada. 9. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. 10. Nephrology, School of Medicine, National University of Ireland Galway, Galway, Ireland. 11. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy. 12. Humanits clinical and research center - IRCCS, Rozzano (Milan), Italy. 13. Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW, Australia. 14. School of Medicine and Public Health, University of Newcastle, Newcastle, Australia. 15. Department of Emergency and Intensive Care, San Gerardo Hospital, Monza, Italy. 16. Department of Medicine, University Health Network and Sinai Health System, Toronto, Canada. 17. Intensive Care Unit, The Canberra Hospital and Australian National University, Canberra, Australia. 18. Anaesthesia and Intensive Care Medicine, School of Medicine, National University of Ireland Galway, Galway, Ireland. john.laffey@nuigalway.ie. 19. Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, Biomedical Sciences Building, National University of Ireland Galway, Galway, Ireland. john.laffey@nuigalway.ie. 20. Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Canada. john.laffey@nuigalway.ie.
Abstract
BACKGROUND: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. METHODS: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). RESULTS: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). CONCLUSIONS: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. TRIAL REGISTRATION: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073.
BACKGROUND: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. METHODS: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). RESULTS: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). CONCLUSIONS: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. TRIAL REGISTRATION: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073.
Authors: Lorenzo Berra; Emanuele Rezoagli; Davide Signori; Aurora Magliocca; Kei Hayashida; Jan A Graw; Rajeev Malhotra; Giacomo Bellani Journal: Intensive Care Med Exp Date: 2022-06-27
Authors: Emanuele Rezoagli; Matteo Petrosino; Paola Rebora; David K Menon; Stefania Mondello; D James Cooper; Andrew I R Maas; Eveline J A Wiegers; Stefania Galimberti; Giuseppe Citerio Journal: Intensive Care Med Date: 2022-10-20 Impact factor: 41.787
Authors: Marta Martín-Fernández; María Heredia-Rodríguez; Paolo Pelosi; Jesús Villar; Eduardo Tamayo; Irene González-Jiménez; Mario Lorenzo-López; Estefanía Gómez-Pesquera; Rodrigo Poves-Álvarez; F Javier Álvarez; Pablo Jorge-Monjas; Juan Beltrán-DeHeredia; Eduardo Gutiérrez-Abejón; Francisco Herrera-Gómez; Gabriella Guzzo; Esther Gómez-Sánchez; Álvaro Tamayo-Velasco; Rocío Aller Journal: Crit Care Date: 2022-01-10 Impact factor: 9.097
Authors: Mervyn Singer; Paul J Young; John G Laffey; Pierre Asfar; Fabio Silvio Taccone; Markus B Skrifvars; Christian S Meyhoff; Peter Radermacher Journal: Crit Care Date: 2021-12-19 Impact factor: 9.097